Clinical Trial Update: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Status update on ONC-392 showing safety, pharmacokinetics, and preliminary efficacy in monotherapy and in combination with anti-PD-1 across multiple advanced so…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Small Cell Lung Cancer

Drugs mentioned

• ONC-392

Snippet

Sponsor: OncoC4, Inc. | Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING